PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK. Electronic address: christopher.butler@phc.ox.ac.uk.\', \'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.\', \'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK; Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa.\', \'Berry Consultants, Austin, TX, USA; Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN, USA.\', \'Berry Consultants, Austin, TX, USA.\', \'Clinical and Experimental Science, National Institute for Health Research (NIHR) Southampton Biomedical Research Centre, Faculty of Medicine, University of Southampton, Southampton, UK.\', \'Rheumatology and Pain Medicine, Bethesda Hospital, Basel, Switzerland.\', \'Independent Researcher, Glatton, UK.\', \'College of Medicine and Health, University of Exeter, Exeter, UK; NIHR Clinical Research Network, NIHR, London, UK.\', \'NIHR Clinical Research Network, NIHR, London, UK; Royal College of General Practitioners, London, UK.\', \'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK; School of Pharmacy and Medical Sciences, University of Bradford, Bradford, UK.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S2213-2600(21)00310-610.1016/S2213-2600(21)00310-6
?:hasPublicationType
?:journal
  • The Lancet. Respiratory medicine
is ?:pmid of
?:pmid
?:pmid
  • 34329624
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all